华纳药厂：获得药品注册证书

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has received approval from the National Medical Products Administration for the registration of Isoproterenol Hydrochloride Injection, which is intended for treating cardiogenic or infectious shock and complete atrioventricular block, as well as cardiac arrest [1] Group 1: Product Approval - The drug name is Isoproterenol Hydrochloride Injection, with registration numbers Guoyao Zhunzi H20256315 and Guoyao Zhunzi H20256316 [1] - The injection is classified as a Category 3 chemical drug under the new registration classification, which is equivalent to passing the consistency evaluation [1] Group 2: Impact on Company - The approval of Isoproterenol Hydrochloride Injection enriches the company's formulation product variety and positively contributes to optimizing the company's product structure [1] - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent performance [1]